Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670834 | 0.91 | SLC16A3 (0.32) | KDM5AKDM5B | |
| SCHEMBL4679140 | 0.88 | LMNA (0.33) | CYP11B1CYP11B2PIM1PIM2 | |
| SCHEMBL4677384 | 0.88 | POLB (0.35) | CYP11B1CYP11B2PIM1PIM2 | |
| SCHEMBL4675917 | 0.86 | CYP11B1 (0.35) | CYP11B1CYP11B2PIM1PIM2 | |
| SCHEMBL4671675 | 0.84 | LMNA (0.34) | CYP11B1CYP11B2PIM1PIM2 | |
| SCHEMBL4672745 | 0.84 | PIM1 (0.32) | PIM1PIM2 | |
| SCHEMBL4674759 | 0.84 | NR3C2 (0.36) | CYP11B1CYP11B2PIM1PIM2 | |
| SCHEMBL5899383 | 0.82 | PIM1 (0.31) | CYP11B1CYP11B2PIM1PIM2 | |
| SCHEMBL4674293 | 0.82 | CYP11B1 (0.33) | CYP11B1CYP11B2PIM1PIM2 | |
| SCHEMBL4676626 | 0.82 | LMNA (0.33) | CYP11B1CYP11B2PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098201-B2 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | FUJISHITA TOSHIO (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6620841-B1 | Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) | SHIONOGI & CO., LTD. (JP) | 2003-09-16 | — | — | US | disclosed |
| EP-1142872-A1 | AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES | SHIONOGI & CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002485-A1 | Heteroaromatic derivatives having an inhibitory activity against HIV integrase | RCOR1, BCOR, CYP8B1 | CYP11B1 63/4885CYP11B2 129/4885PIM1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.